User Photo Jack West
Lung Cancer: My Top 5 Abstracts to See in Lung Cancer at ASCO 2023 Jack West MD - Article
Lung Cancer: My Top 5 Abstracts to See in Lung Cancer at ASCO 2023 Jack West MD - Article
1,606 Views
1 week Ago
Jack West
Want to watch this again later?
Sign in to add this video to a playlist. Login
Lung Cancer: My Top 5 Abstracts to See in Lung Cancer at ASCO 2023 Jack West MD
Lung Cancer: My Top 5 Abstracts to See in Lung Cancer at ASCO 2023 Jack West MD
1,583 Views
1 week Ago
Jack West
Want to watch this again later?
Sign in to add this video to a playlist. Login
Pembrolizumab's approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC Jack West MD
Pembrolizumab's approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC Jack We...
51 Views
3 months Ago
Jack West
Want to watch this again later?
Sign in to add this video to a playlist. Login
Pembrolizumab's approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC Jack West MD
Pembrolizumab's approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC Jack We...
296 Views
3 months Ago
Jack West
Want to watch this again later?
Sign in to add this video to a playlist. Login
3.2K Views in the last 30 days
User Photo Cancer News
Molecule RRx-001 Receives Fast Track Designation From the FDA - EpicentRx
Molecule RRx-001 Receives Fast Track Designation From the FDA - EpicentRx
290 Views
1 week Ago
Cancer News
Want to watch this again later?
Sign in to add this video to a playlist. Login
Molecule RRx-001 Receives Fast Track Designation From the FDA - EpicentRx
Molecule RRx-001 Receives Fast Track Designation From the FDA - EpicentRx
55 Views
1 week Ago
Cancer News
Want to watch this again later?
Sign in to add this video to a playlist. Login
Spatial Biology: Lunaphore's COMET Portfolio Becomes the First Complete and Inclusive Solution Deborah Heintze
Spatial Biology: Lunaphore's COMET Portfolio Becomes the First Complete and Inclusive Solution Deborah Heintze
47 Views
2 weeks Ago
Cancer News
Want to watch this again later?
Sign in to add this video to a playlist. Login
Gamma Delta: Two Phase 1 INDs Approved Announces Jeff Liter CEO Luminary Therapeutics
Gamma Delta: Two Phase 1 INDs Approved Announces Jeff Liter CEO Luminary Therapeutics
36 Views
3 weeks Ago
Cancer News
Want to watch this again later?
Sign in to add this video to a playlist. Login
522 Views in the last 30 days
User Photo Cancer
Tito R. Mendoza, PhD, MS, MEd @MDAndersonNews #Immunotherapy #Cancer #Research Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory
Tito R. Mendoza, PhD, MS, MEd @MDAndersonNews #Immunotherapy #Cancer #Research Evaluating the psychometric properties...
60 Views
2 years Ago
Cancer
Want to watch this again later?
Sign in to add this video to a playlist. Login
Jonathan Shamash MBChB, MD, MRCP @NHSBartsHealth @NHSEnglandLDN #TesticularCancer #Cancer #Research The Impact Of A SMDT On Decision- Making in Testicular Cancers
Jonathan Shamash MBChB, MD, MRCP @NHSBartsHealth @NHSEnglandLDN #TesticularCancer #Cancer #Research The Impact Of A S...
93 Views
2 years Ago
Cancer
Want to watch this again later?
Sign in to add this video to a playlist. Login
Vered Stearns, MD @VeredStearns @hopkinskimmel #BreastCancer #Cancer #Research Talking An Individualized Approach To Preventing And Treating Triple Negative Breast Cancer in African Ameri...
Vered Stearns, MD @VeredStearns @hopkinskimmel #BreastCancer #Cancer #Research Talking An Individualized Approach To ...
57 Views
2 years Ago
Cancer
Want to watch this again later?
Sign in to add this video to a playlist. Login
Mallinckrodt Receives Approval in Japan of the CELLEX® Extracorporeal Photopheresis System for Treatment of Chronic Graft Versus Host Disease
Mallinckrodt Receives Approval in Japan of the CELLEX® Extracorporeal Photopheresis System for Treatment of Chronic ...
12 Views
2 years Ago
Cancer
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 Views in the last 30 days
User Photo SABCS
PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer
PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer
33 Views
4 months Ago
SABCS
Want to watch this again later?
Sign in to add this video to a playlist. Login
PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer
PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer
54 Views
4 months Ago
SABCS
Want to watch this again later?
Sign in to add this video to a playlist. Login
PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer
PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer
253 Views
4 months Ago
SABCS
Want to watch this again later?
Sign in to add this video to a playlist. Login
ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial
ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial
26 Views
4 months Ago
SABCS
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 Views in the last 30 days
User Photo ASH
Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes
Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes
11 Views
4 months Ago
ASH
Want to watch this again later?
Sign in to add this video to a playlist. Login
Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes
Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes
62 Views
4 months Ago
ASH
Want to watch this again later?
Sign in to add this video to a playlist. Login
Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes
Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes
122 Views
4 months Ago
ASH
Want to watch this again later?
Sign in to add this video to a playlist. Login
Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL
Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL
20 Views
4 months Ago
ASH
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 Views in the last 30 days
User Photo Renier Brentjens, MD, PhD
CAR T-Cell Therapy: Promising Results Against Small Cell Lung Cancer Renier Brentjens MD
CAR T-Cell Therapy: Promising Results Against Small Cell Lung Cancer Renier Brentjens MD
55 Views
3 weeks Ago
Renier Brentjens, MD, PhD
Want to watch this again later?
Sign in to add this video to a playlist. Login
311 Views in the last 30 days
User Photo Professor Nagesh Kalakonda
Tafasitamab: Final Results of Five-Year Safety and Efficacy Study (Phase II L-MIND) Prof. Kalakonda
Tafasitamab: Final Results of Five-Year Safety and Efficacy Study (Phase II L-MIND) Prof. Kalakonda
308 Views
1 month Ago
Professor Nagesh Kalakonda
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 Views in the last 30 days
User Photo Annual Meeting
Pembrolizumab + Adoptive Cell Therapy Melanoma with T-Cell data
Pembrolizumab + Adoptive Cell Therapy Melanoma with T-Cell data
98 Views
10 months Ago
Annual Meeting
Want to watch this again later?
Sign in to add this video to a playlist. Login
I-SPY2 HER2+ and HER2- Precisely ID'd with 53 Gene Signatures
I-SPY2 HER2+ and HER2- Precisely ID'd with 53 Gene Signatures
210 Views
10 months Ago
Annual Meeting
Want to watch this again later?
Sign in to add this video to a playlist. Login
Bevacizumab FOLFOXIRI - Atezolizumab Metastatic Colorectal Cancer
Bevacizumab FOLFOXIRI - Atezolizumab Metastatic Colorectal Cancer
78 Views
10 months Ago
Annual Meeting
Want to watch this again later?
Sign in to add this video to a playlist. Login
BRCA1, BRCA2 or PALB2 in pancreatic cancer.
BRCA1, BRCA2 or PALB2 in pancreatic cancer.
155 Views
11 months Ago
Annual Meeting
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 Views in the last 30 days
User Photo Michael Pishvaian
Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and nab-paclitaxel for Pancreatic Cancer...
Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemci...
237 Views
2 months Ago
Michael Pishvaian
Want to watch this again later?
Sign in to add this video to a playlist. Login
Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and nab-paclitaxel for Pancreatic Cancer...
Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemci...
72 Views
2 months Ago
Michael Pishvaian
Want to watch this again later?
Sign in to add this video to a playlist. Login
Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit
Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit
12 Views
2 months Ago
Michael Pishvaian
Want to watch this again later?
Sign in to add this video to a playlist. Login
Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit
Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit
188 Views
2 months Ago
Michael Pishvaian
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 Views in the last 30 days
User Photo Oncology Conferences
Dr. Emrullah Yilmaz Unveils the Potential of BCA101 in Cancer Treatment
Dr. Emrullah Yilmaz Unveils the Potential of BCA101 in Cancer Treatment
0 Views
53 minutes Ago
Oncology Conferences
Want to watch this again later?
Sign in to add this video to a playlist. Login
Unlocking New Treatments: The Journey of Squamous Cell Cancer
Unlocking New Treatments: The Journey of Squamous Cell Cancer
1 Views
1 hour Ago
Oncology Conferences
Want to watch this again later?
Sign in to add this video to a playlist. Login
Ruxolitinib Safety and Feasibility in NHGGs: Final Toxicity Report
Ruxolitinib Safety and Feasibility in NHGGs: Final Toxicity Report
3 Views
7 hours Ago
Oncology Conferences
Want to watch this again later?
Sign in to add this video to a playlist. Login
Trastuzumab PHERGain Trial: Unveiling 3-Year iDFS in HER2+ Early Breast Cancer
Trastuzumab PHERGain Trial: Unveiling 3-Year iDFS in HER2+ Early Breast Cancer
3 Views
7 hours Ago
Oncology Conferences
Want to watch this again later?
Sign in to add this video to a playlist. Login
175 Views in the last 30 days